GUTS vs TMDX
GUTS: Fractyl Health is a clinical-stage medical device and gene therapy company developing the Revita mucosa resurfacing procedure and Rejuva gene therapy platform for type 2 diabetes and metabolic disorders. TMDX: TransMedics commercializes the only FDA-approved portable warm perfusion platform for multi-organ transplantation, replacing cold storage to dramatically increase donor organ utilization and post-transplant outcomes.
Side-by-side fundamentals
| Metric | GUTS | TMDX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $0.76 | $71.20 | |
| Market cap as of 2026-07-23 | $123M | $2.5B | |
| P/E as of 2026-07-23 | n/a | 14.43 | |
| PEG as of 2026-07-23 | n/a | 0.08 | |
| Net margin as of 2026-07-23 | -73864.5% | +27.0% | TMDX higher |
| Gross margin as of 2026-07-23 | +46.2% | +59.1% | TMDX higher |
| Operating margin as of 2026-07-23 | -100571.0% | +14.8% | TMDX higher |
| ROE as of 2026-07-23 | -852.1% | +41.9% | TMDX higher |
| ROA as of 2026-07-23 | -148.1% | +15.8% | TMDX higher |
| Debt / equity as of 2026-07-23 | 1.41 | 1.73 | GUTS lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +30.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +86.4% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 1.45 | 1.94 | |
| 1-year return as of 2026-07-22 close | -57.2% | -32.6% | TMDX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.